Every 8-K that BLDEW (BLDEW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BLDEW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLDEW filings page.
Strata Critical Medical, Inc. reported results of its annual stockholder meeting held on May 28, 2026. Stockholders elected Class II directors William A. Heyburn and Andrew Lauck to serve until the 2029 annual meeting. Heyburn received 46,050,902 votes for and 505,421 withheld, while Lauck received 39,525,159 for and 7,031,164 withheld, with 12,687,496 broker non-votes for each.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 58,946,832 votes for, 65,815 against, and 231,172 abstentions. In an advisory vote, stockholders approved executive compensation with 38,497,962 votes for, 8,022,682 against, 35,679 abstentions, and 12,687,496 broker non-votes.
Strata Critical Medical reported strong first quarter 2026 results, with total revenue rising 87.4% year-over-year to $67.4 million, driven by 32.4% growth in Logistics revenue and the addition of its Clinical business. Gross profit doubled to $14.1 million, lifting gross margin to 21.0% from 19.6%.
The company generated net income from continuing operations of $2.4 million, compared with a loss of $1.6 million a year earlier, and delivered Adjusted EBITDA of $6.4 million, up sharply from $0.4 million. Operating cash flow reached $3.9 million, and Strata ended the quarter with $58.8 million in cash and short-term investments.
Clinical revenue rose 12.7% sequentially to $19.8 million, with Clinical gross profit up 29.2% versus Q4 2025. The company completed a bolt-on acquisition of Ohio Valley Perfusion Associates and reiterated its full-year 2026 guidance for revenue of $260–275 million, Adjusted EBITDA of $29–33 million, and free cash flow before aircraft and engine acquisitions of $15–22 million.
Strata Critical Medical reported very strong growth for Q4 2025, with revenue rising 83.5% year over year to $66.8 million. Logistics revenue, which reflects organic growth, increased 35.3% to $49.2 million, while new Clinical operations contributed $17.6 million following the Keystone acquisition.
Gross profit nearly doubled to $14.4 million and gross margin improved to 21.6%. The net loss from continuing operations narrowed to $5.4 million, but the company remained unprofitable on a GAAP basis. Non-GAAP Adjusted EBITDA jumped to $7.0 million from $1.1 million.
For full year 2025, revenue reached $197.1 million and Adjusted EBITDA was $14.1 million, both above the high end of guidance. Strata raised its 2026 outlook to revenue of $260–275 million and Adjusted EBITDA of $29–33 million, and now expects free cash flow before aircraft and engine acquisitions of $15–22 million.
Strata Critical Medical, Inc. entered into a new secured, asset-based revolving credit facility of up to $30.0 million with JPMorgan Chase Bank, N.A. and other lenders. The agreement allows the facility to be increased by up to an additional $20.0 million, providing extra borrowing capacity if conditions are met.
The ABL facility matures on January 30, 2029 and will bear interest, at Trinity Air Medical’s election, at an adjusted Term SOFR-based fixed rate plus a 2.00% margin or a one‑month Term SOFR floating rate plus a 2.00% margin. A 0.25% annual commitment fee applies to unused amounts.
The loans are guaranteed by Strata Critical Medical and its subsidiary Strata Critical, Inc. and are secured by first‑priority liens on substantially all personal property of the loan parties. The agreement contains customary covenants and events of default, including a springing minimum fixed charge coverage ratio of 1.05 to 1.00 when availability falls below specified thresholds. Proceeds are intended for working capital and general organizational purposes.